

A Clinical Study of B007 in the Treatment of Pemphigus.

NCT06454357

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Shanghai Jiaolian Drug Research and Development Co., Ltd
Enrollment	132 participants

Key Eligibility Criteria

Inclusion (4)

- Subjects who voluntarily participate in this study and sign informed consent form;
- Subjects who meet the clinical manifestations of pemphigus and are clinically diagnosed as prescribed diseases;
- Subjects with first diagnosis or relapse;
- Subjects who have the ability to follow the study protocol as determined by the investigator.

Exclusion (13)

- Subjects diagnosed with prescribed diseases;
 - Since the diagnosis of pemphigus, Disease duration >4 years;
 - Subjects using prescribed drugs;
 - Presence of a specified disease or history of disease;
 - The subjects has prescribed examination abnormalities that are assessed as unsuitable for participation in the study by the investigator;
- ... and 8 more (see full listing online)

Locations (12 total)

Peking University First Hospital, Beijing, China
The Second Xiangya Hospital of Central South University, Changsha, China
Chengdu Second People's Hospital, Chengdu, China
... and 9 more locations